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Abstract 
Background: One of the promising methods in fertility preservation among women 
with cancer is cryopreservation of ovarian cortex but there are many drawbacks such 
as apoptosis and considerable reduction of follicular density in the transplanted 
ovary. One solution to reduce ischemic damage is enhancing angiogenesis after 
transplantation of ovarian cortex tissue. 
Objective: The aim of this study was to investigate the effect of Setarud, on 
angiogenesis in transplanted human ovarian tissue. 
Materials and Methods: In this case control study, twenty four nude mice were 
implanted subcutaneously, with human ovarian tissues, from four women. The mice 
were randomly divided into two groups (n=12): the experimental group was treated 
with Setarud, while control group received only vehicle. Each group was divided 
into three subgroups (n=4) based on the graft recovery days post transplantation 
(PT). The transplanted fragments were removed on days 2, 7, and 30 PT and the 
expression of Angiopoietin-1, Angiopoietin-2, and Vascular endothelial growth 
factor at both gene and protein levels and vascular density were studied in the 
grafted ovarian tissues. 
Results: On the 2nd and 7th day PT, the level of Angiopoietin-1 gene expression in 
case group was significantly lower than that in control group, while the opposite 
results were obtained for Angiopoietin-2 and Vascular endothelial growth factor. 
These results were also confirmed at the protein level. The density of vessels in 
Setarud group elevated significantly on day 7 PT compared to pre-treatment state. 
Conclusion: Our results showed that administration of Setarud may stimulates 
angiogenesis in transplanted human ovarian tissues, although further researches are 
needed before a clear judgment is made. 
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Introduction 
 
any cancer patients become infertile 
after treatment and this can be an 
important concern for younger people. 
One of the promising methods to restore 
fertility of women patients is cryopreservation 
of ovarian cortex before staring cancer 
treatment. There are many drawbacks such 
as apoptosis and considerable reduction of 
follicular density in the transplanted ovary (1-
3). Some studies have shown that these 
problems mainly result from ischemic 
damages and not from freezing/thawing 
process of the tissue (1). One solution to 
reduce ischemic damage is enhancing 
angiogenesis after transplantation of ovarian 
cortex tissue (1, 4). 
It seems that various angiogenic factors 
are expressed in the ovary. Vascular 
endothelial growth factor (VEGF) and 
angiopoietins (Ang) due to their specific 
effects on endothelial cells have more 
important roles (5-10). 
VEGF has a crucial role in angiogenesis by 
acting through migration, proliferation, and 
differentiation of endothelial cells, formation of 
immature veins, and vascular permeability (1, 
5, 11). Angiopoietin, another family of growth 
factors, has an important role in effective 
function of VEGF, remodeling, branching, 
maturation, and perseverance of veins 
through interaction with extra cellular matrix 
(5, 7-10, 12, 13).  
Setarud (IMODTM) is a mixture of herbal 
extract of different plants (Tanacetum vulgare, 
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Rosa canina, Urtica dioica) which various 
studies have shown its beneficial effects on 
immune system, lipid metabolism, liver 
function, and inflammatory processes (14-18). 
Setarud contains various compounds such as 
selenium, beta carotene and tannin that some 
studies have shown their effects on 
angiogenesis (19-26). 
Selenium as selenomethionine has potent 
angiogenic effects in the corneal pocket or 
chorioallantoic membrane assays. It was 
shown that selenium induces migration and 
proliferation of aortic cells leading to a three-
fold increase in cell proliferation (24). 
There are reports on the effect of beta-
carotene on the stimulation of angiogenesis. It 
can induce angiogenic gene expression and 
promotes cell differentiation by binding to 
nuclear retinoid receptors (20, 21, 25, 27). 
Tannin has also angiogenic activity. It seems 
that tannin increases the amount of newly 
formed capillaries by up-regulating VEGF 
expression (22). 
Since successful transplantation of ovarian 
cortex is dependent on the reduction of 
apoptosis and maintenance of follicular 
density and angiogenesis is one of the best 
solutions for inhibiting ischemic damages, the 
aim of this study was to assess the effect of 
Setarud on the promotion of angiogenesis in 
transplanted fragments of human ovary to 
nude mice by measuring the level of gene and 
protein expression of VEGF, Ang-1 and Ang-2 
which are effective in angiogenesis and 
evaluation of vascular density. 
 
Materials and methods 
 
Experimental design 
This case control study was conducted at 
Avicenna Research Institute in order to 
assess the potential effects of Setarud 
(IMODTM) on induction of angiogenesis in 
transplanted human ovarian tissues. Human 
ovarian fragments were grafted 
subcutaneously to twenty four mature (aged 6 
to 8 weeks) female B6cg nude mice. The mice 
were then randomly divided into two groups 
(n=12 mice per group) of case and control: the 
case group was treated with Setarud 1 ml/kg 
(30 mg/ml), (Rose Pharmed Co., Iran), every 
day, while control group received only vehicle 
(8.6 % ethanol v/v) (Merck, Darmstadt, 
Germany). The animals in each group were 
divided into three subgroups of 4 mice each 
based on the graft recovery days post 
transplantation (PT). All injections were 
performed as intravenous (IV) from day 1 until 
day 7 for both groups and after that until day 
30 were injected subcutaneously. The grafts 
were recovered from the subgroups on the 
2nd, 7th or 30th day after transplantation. 
 
Ovarian samples 
The use of human tissue for this study was 
approved by the local ethics committee of 
Avicenna Research Institute. Ovarian biopsy 
specimens were taken from four women 
(between 23 and 38 years of age), after 
obtaining written informed consent. They were 
all undergoing surgery for sex reversal or 
ovarian cyst. They did not have endometriosis 
or other ovarian diseases. 
In the operating room, immediately after 
biopsy specimen retrieval, ovarian tissue was 
immersed in a solution of Dulbecco´s 
minimum essential medium (Sigma, St. Louis, 
Missouri, USA) supplemented with 10% 
human serum and transported to the 
laboratory on ice. Each ovarian biopsy 
specimen was cut into pieces of 2-3 mm3 and 
implanted to nude mice SC. 
 
Animals 
Twenty-four 8 to 10 weeks-old female B6cg 
nude mice weighing between 20-30 g were 
obtained from Tehran University of Medical 
Sciences. The animals were housed under 
specific pathogen-free conditions with a 
constant temperature (22-25ºC), relative 
humidity (55%) and 12-h dark/light cycles. All 
procedures, tests, and injections were 
performed under a laminar flow hood in a 
positive pressure room. Approval for the study 
was obtained from the local ethical committee 
on animal experiments. The animals were 
maintained in accordance with Animal Care 
and Use Committee Regulations. 
 
Anesthesia and ovarian transplantation 
The mice were anesthetized by 
intraperitoneal injection of ketamine (Alfasan, 
Woerden, NL) 100 mg/Kg and Xylazine 
(Alfasan) 10 mg/Kg. The incision site was 
thoroughly disinfected with 70% ethanol 
(Merck) and betadine. Human ovarian pieces 
were grafted under the back skin of each 
mouse (28, 29). The mice were sacrificed 2, 7, 
and 30 days PT and ovarian fragments were 
removed from each animal. One fragments of 
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transplanted ovarian tissue was immersed in 
10% formalin (Merck) for histological 
evaluation and the others were frozen in liquid 
nitrogen and then stored at -70ºC for 
molecular evaluations. 
 
Histological evaluation 
Briefly, fixed ovarian fragments in 10% 
formalin were processed into paraffin blocks 
and then specimens were cut into serial 
sections with 3-5 micron thickness. Moreover, 
they were stained according to Hematoxylin 
and Eosin (Merck) (H & E) staining protocol. 
The number of single layer vessels for each 
tissue was counted in at least 5 sections in 
high power field (HPF) and averaged and 
averaged. The data for each experimental 
group was shown as the mean density of 
vessels per microscopic field at 
400×magnification (vessel number/HPF). 
 
Analysis of VEGF, Ang-1, and Ang-2 gene 
expression by real time PCR 
Total RNA was extracted using a Trizol 
reagent (Invitrogen Life Technologies, 
Carlsbad, CA, USA) according to the 
manufacturer’s instruction. The final RNA 
pellet was washed with 75% ethanol, air dried, 
and then dissolved in diethy l pyrocarbonate 
treated water (CinnaGen, Tehran, Iran). The 
concentration and purity of RNA was 
determined by biophotometer (Eppendorf, 
Hamburg, Germany). First strand cDNA was 
generated with 1 µg total RNA using the cDNA 
Synthesis Kit (Roche Diagnostics GmbH, 
Mannheim, Germany). The house keeping 
gene for normalization was Hypoxanthine 
guanine phosphoribosyl transferase (HPRT). 
Real-time quantitative PCR was performed 
using ABI 7500 real time PCR system and 
SYBR-Green Premix Ex Taq kit (TAKARA, 
Otsu, Shiga, Japan). The reactions were 
performed with the following settings: 95°C for 
10 s (initial denaturation), 40 cycles of 
denaturation at 95°C for 5 s, and annealing at 
56°C for 30 s (for Ang-1 and Ang-2), or 60°C 
for 30 s (for HPRT and VEGF), and extension 
at 72°C for 30 s each.  
 
Western blot analysis 
The extraction of protein from ovarian 
fragments was down on ice with lysis buffer 
containing (Tris-HCl 20 mM, NaCl 137 mM, 
glycerol 10% v/v, NP40 1% v/v, EDTA 2 mM, 
and protease inhibitor cocktail (Sigma). 
Protein lysates were then centrifuged and 
their protein concentrations were determined 
using BCA protein assay kit (Thermo Scientific 
Pierce, Rockford, IL, USA). The extracted 
proteins were resolved on a 12% SDS-PAGE 
and transferred to PVDF membranes. After 
blocking by incubating the membranes with 
blocking solution containing 5% non-fat milk 
overnight at 4°C, the membranes were 
incubated with human-specific primary 
antibodies including rabbit anti-VEGF (Abcam, 
Cambridge, UK), goat anti-Ang-1 (Sigma), 
rabbit anti-Ang-2 (Abcam) or rabbit anti-β-
actin (Abcam) diluted 1: 1000 in 3% non-fat 
milk for 2 hr at room temperature. The 
membranes were washed in Tris-buffered 
saline with 0.05% Tween-20 and then 
incubated with peroxidase-conjugated sheep 
anti-rabbit Ig (Avicenna Research Institute, 
Tehran, Iran) diluted 1: 3500, or rabbit anti-
goat Ig (Razi BioTech, Tehran, Iran) diluted 
1:4000 in 3% non-fat milk for 1 hr at room 
temperature. The peroxidase activity was 
visualized using an enhanced 
chemiluminescence (ECL) kit (GE Health 
care, Uppsala Sweden) and band densities 
were analyzed using AlphaEase software. The 
relative expression levels of proteins (VEGF, 
Ang-1 and Ang-2) were indicated by 
comparing density of each band with that of 
the internal control, β-actin. 
 
Statistical analysis 
The total expression ratio of the genes of 
interest at three time points was compared 
between Setarud (IMODTM) and control groups 
using a randomization test implemented in the 
relative expression software tool (REST), 
which is an Excel-based application for 
comparison and statistical analysis of relative 
expression results in qRT-PCR (30). The 
same software was also used for group wise 
comparison of the gene expression between 
each group and pre-treatment state. Vascular 
densities in the two groups were compared by 
Wilcoxon signed rank test using SPSS11.5 
software (Statistical Package for the Social 
Sciences, SPSS Inc, Chicago, Illinois, USA). 
Differences were considered significant when 
p<0.05. 
 
Results 
 
Analysis of vascular density 
Evaluation of vascular density using 
nonparametric test showed that the density of 
vessels in Setarud (IMODTM) group elevated 
significantly at day 7 PT compared to pre-
treatment state (p=0.043) (Figures 1-A and B). 
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Ang-1 expression 
Analysis of Ang-1 gene expression by real-
time RT-PCR showed significant decrease in 
the Setarud (IMODTM) group on days 2, 7 and 
30 compared to pre-treatment state (p=0.001, 
p=0.001 and p=0.038 respectively). In control 
group, the gene expression rate revealed to 
be significantly lower only on day 7 PT as 
compared to pre-treatment state (p=0.001) 
(Figure 2-A). Compared to the control group, 
the level of Ang-1 gene expression on days 2 
and 7 were significantly lower in Setarud 
group (p=0.007 and p=0.008 respectively), 
(Table I). Data obtained by Western blot 
analysis showed the similar pattern of Ang-1 
protein expression in both groups and time 
intervals were examined (Figure 3). 
 
Ang-2 expression 
Gene expression of Ang-2 in Setarud 
(IMODTM) and control groups showed opposite 
patterns throughout the study (Figure 2-B); the 
statistical analysis, however, did not show any 
significant variation of the gene in both groups 
compared to pre-treatment state. Comparison 
between the Setarud (IMODTM) and control 
groups showed significant increase in gene 
expression on days 2 PT (p=0.007) and lower 
gene expression on day 7 PT (p=0.028) in 
Setarud group (Table I). The pattern of Ang-2 
protein expression followed that of Ang-2 
gene, but no strict consistency at all time 
periods was observed (Figure 3). 
 
Ang-2: Ang-1 expression 
It seems that evaluation of Ang-1 or Ang-2 
separately did not give a precise picture of 
their contribution in angiogenesis but their 
ratio might be more important. With this 
assumption, the Ang-2: Ang-1 ratio was 
calculated for each PT time interval and was 
compared between the control and Setarud 
groups. It was surprising that this ratio was 
found to be significantly higher (p=0.001) in 
the Setarud (IMODTM) group compared with 
the control group on day 2 PT. This ratio was 
inverted on day 7 PT (p=0.03) (Figure 2-C).  
 
VEGF expression 
Expression rate of VEGF gene in Setarud 
(IMODTM) group elevated significantly on days 
2, 7 and 30 PT in comparison to pre-treatment 
state (p=0.001, p=0.001 and p=0.021, 
respectively), (Figure 2-D). The VEGF was 
significantly up-regulated on days 2 and 7 in 
the Setarud (IMODTM) group compared with 
the control group (p=0.045 and p=0.045, 
respectively), (Table I). The pattern of VEGF 
protein expression (Figure 3) was in line with 
what was found at the gene level (Figure 2-D). 
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Figure 2. Relative expression of Angiopoietin-1, Angiopoietin-2, and Vascular endothelial growth factor genes in transplanted human ovarian tissues 
in Setarud (IMODTM) and control groups at different time intervals after transplantation. Nude mice were treated with Setarud or vehicle after 
transplantation with human ovarian tissues. On days 2, 7 and 30 post transplantation, ovarian fragments were removed and the expression of Ang-1 
(A), Ang-2 (B), Ang-1/Ang-2 ratio (C) and VEGF (D) were assessed by quantitative real time PCR. All comparisons were made compared to pre-
treatment state (0).  ٭p<0.05, ٭٭p<0.01                 Abs gene reg: Absolute gene regulation. 
 
 
 
 
Table I. The total expression ratio of the genes of interest in Setarud (IMODTM) group relative to control group is presented at each 
time point (2nd, 7th and 30th day after transplantation) 
 
 
*Pair-Wise fixed Reallocation Randomization Test (Permutation test with 2000 iterations) 
Significant down- or up-regulations of the genes are highlighted. 
PT: Post transplantation; SEM: Standard error of mean; Ang-1: Angiopoietin-1; Ang-2: Angiopoetin-2; VEGF: Vascular endothelial growth factor 
 
 
 Day 2 PT Day 7 PT Day 30 PT 
 
Ang-1 Ang-2 VEGF Ang-1 Ang-2 VEGF Ang-1 Ang-2 VEGF 
Relative expression 0.15 3.74 1.24 0.33 0.30 1.42 0.450 0.45 1.16 
SEM 0.11 3.8 0.89 0.24 0.28 0.51 0.34 0.41 0.65 
p-value 0.007 0.007 0.045 0.008 0.028 0.045 0.233 0.254 0.065 
Fold increase/decrease -6.64 3.74 1.24 -3.02 -3.31 1.42 -2.22 -2.23 1.16 
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Figure 3. Western blot analysis of ovarian Angiopoietin-1, Angiopoietin-2, and Vascular endothelial growth factor expression in Setarud (IMODTM), 
and control groups.                                 Lane1: pre-treatment ovary 
Lanes 2-4: days 2, 7, 30 post transplantation in Setarud (IMODTM) group, respectively 
Lanes 5-7: days 2, 7, 30 post transplantation in control group, respectively  
 
 
Discussion 
 
Our results showed a beneficial effect of 
Setarud (IMODTM) on triggering angiogenesis 
process in heterptopic transplanted ovarian 
cortex leading to inhibition of ischemic 
damages and preservation of follicular 
density. 
Data on gene expression level of Ang-1 
clearly showed gene down regulation in 
Setarud (IMODTM) group on 2nd and 7th days 
in which these down-regulations were 
significantly lower than vehicle-treated 
ovaries. Studies have shown that Ang-1 has 
anti-inflammatory and anti-apoptotic effects on 
endothelial cells during the plastic phase of 
angiogenesis (31-36). Reportedly, in plastic 
phase of angiogenesis, the decrease in the 
level of Ang-1 gene expression resulted in 
loss of integrity of existing vasculature. This 
process may trigger the development of newly 
formed vessels (7). It seems that Setarud 
(IMODTM) stimulates angiogenesis and 
induction of new blood vessels maturation by 
significant reduction in Ang-1 expression soon 
after transplantation. In contrast to the 
expression level of Ang-1, the expression of 
Ang-2 on days 2 and 7 were higher in Setarud 
(IMODTM) group compared to the control 
group. It has been shown that increase of 
Ang-2 to Ang-1 ratio causes loss of vascular 
integrity and consequently stimulation of 
angiogenesis (7, 8, 37). 
The pattern of VEGF gene expression 
during the study period was similar in both 
groups with initial increase followed by 
decrease and there was a significant 
difference between the two groups, which 
suggests apparent effect by Setarud on VEGF 
expression. There are many reports on the 
synergistic effect of VEGF and Ang-2 on the 
stimulation of angiogenesis (5, 6, 8-10, 12, 38-
51), suggesting a beneficial effect of Setarud 
(IMODTM) on initiation of angiogenesis. 
The results of Western blot analysis of 
protein, Ang-1, Ang-2 and VEGF confirmed 
the pattern of their gene expression, although, 
in some time intervals no strict consistency 
was observed which may be related to small 
number of studied cases. Setarud (IMODTM) 
treatment also significantly increased the 
vascular density at day 7 PT with the 
normalization of neovascularization on day 30 
PT. Therefore, it seems that simultaneous 
increment of Ang-2 and VEGF expression in 
the Setarud group may accelerate 
angiogenesis process shortly after 
transplantation. However, further studies with 
more samples are needed for confirmation of 
this hypothesis. 
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Setarud (IMODTM), as the extract of three 
plants, contains several pharmaceutical active 
compounds. The anti-oxidant effects of this 
drug have been documented by other studies 
(14, 15). Such consequence may also be 
responsible for the beneficial effects observed 
in our study. It has been shown that selenium, 
beta-carotene and tannin as the active 
components of the extract can trigger 
angiogenesis (19-26). Since no report on the 
differential effects of each component of the 
extract is available, it cannot be determined 
confidently which components or their 
combination is responsible for the stimulation 
of angiogenesis. 
 
Conclusion 
 
In conclusion, our data suggest that 
Setarud (IMODTM) induces angiogenesis and 
reduces ischemic damages in heterotopic 
transplanted human ovarian tissue. 
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